ClinicalTrials.gg
RecruitingNCT07627763COPD-BPCO 2Updated Jun 4, 2026

Prospective Dynamic Cohort Study of Phenotypic Profiles in Patients With Chronic Obstructive Pulmonary Disease

An observational study in COPD, sponsored by Initiatives Bronchopneumopathie Chronique Obstructive (BPCO). Recruiting at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Initiatives Bronchopneumopathie Chronique Obstructive (BPCO) · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France — 71 open to participants now, 81 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · France.

Planned enrollment
17th of 119
500 · median 100
Started
2026
with 19 others
Observational
119 of 406
20 open now
Primary completion
2029-12
later than 74 of 80 live
Registered
395th of 406
by date

Among the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, this one is the 17th largest by planned enrollment of the 119 observational ones that give a count, is one of 20 that started in 2026, is one of 119 observational ones, reaches primary completion later than 74 of the 80 other live ones, and was the 395th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

71 of the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France are open now. Recruiting first, the newest first:

65 more — sign in →

All 71 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, or all of them as a file.
02

Study summary

This prospective, multicenter, real-world observational cohort study will describe phenotypic profiles, patient characteristics, and treatments in adults with stable chronic obstructive pulmonary disease (COPD). The profiles observed in the current cohort will be compared with those of patients recruited between 2005 and 2018 in the previous COPD-BPCO 1 cohort. Patients will be followed for at least 3 years as part of routine care, with no study-specific visit or treatment.

Read the detailed description

COPD is a heterogeneous disease, and patient characteristics may be associated with prognosis and treatment response. The previous Initiative BPCO cohort recruited 1,720 subjects between 2005 and 2018 and identified clinically relevant COPD phenotypes, including subgroups associated with mortality risk. Because diagnostic strategies, risk factors, comorbidity management, and COPD treatments have evolved, this new prospective dynamic cohort will assess whether current COPD phenotypes differ from those previously identified and whether classification and regression tree (CART) algorithms developed in the previous cohort remain applicable. Data will be collected during routine care from hospital pulmonology centers in France. Baseline and follow-up data may include demographics, risk factors, comorbidities, usual treatments, patient-reported questionnaires, pulmonary function, arterial blood gases, 6-minute walk test, imaging, biology results, exacerbations, and mortality status.

03

Conditions studied

  • COPD

Keywords

  • quality of life
  • dyspnea
  • pulmonary function
  • exacerbations
  • COPD
  • CART
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with stable COPD followed in French hospital pulmonology centers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age 18 years or older.

  • Stable , defined as no exacerbation requiring treatment during the previous 4 weeks.
  • Confirmed COPD diagnosis based on post-bronchodilator /FVC \< 70%

Exclusion criteria

Exclusion Criteria:

  • Main diagnosis of bronchiectasis, asthma, or any other significant respiratory disease.
  • Patients under legal protection.
  • Pregnant women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with stable COPD

    Adults with stable COPD confirmed by post-bronchodilator FEV1/FVC \< 70%, recruited during routine pulmonology care

    Other: Routine care / no study-specific intervention

Interventions

  • OtherRoutine care / no study-specific intervention

    Patients will be managed according to usual care at the investigator's discretion. The study does not assign any treatment, medicinal product, or medical device.

06

What researchers measure

Primary outcomes

  1. Identification and description of COPD phenotypic profiles

    COPD phenotypic subgroups will be defined using unsupervised clustering and described according to patient characteristics, treatments, pulmonary function, symptoms, exacerbations, clinically important deterioration, and mortality

    Time frame: Baseline and up to 3 years

Secondary outcomes

  1. Comparison of phenotypic profiles with the previous COPD-BPCO 1 cohort

    Baseline and up to 3 years

    Time frame: Current profiles will be compared with those observed in the previous cohort recruited between 2005 and 2018.

  2. Prognosis of current patients compared with the previous cohort

    Prognosis will be explored using mortality at 3 years, exacerbations, pulmonary function, dyspnea, health status, treatment modifications, and clinically important deterioration

    Time frame: 3 years

  3. Applicability of previously developed CART algorithms

    Classification and regression tree algorithms developed from COPD-BPCO 1 will be applied to the new cohort and, if needed, new classification trees will be developed.

    Time frame: Through study completion, an average of 3 years

  4. Adverse events

    Number and detailed description of adverse events collected as part of the study, although no adverse event related to the study itself is expected.

    Time frame: Through study completion, an average of 3 years

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2029, 43 months after the start.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 43 months is above that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 4, 2026
StartActual
May 1, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07627763
Lead sponsor
Initiatives Bronchopneumopathie Chronique Obstructive (BPCO)
Collaborators
Clin-Experts
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
May 1, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jun 4, 2026

Study contacts

Renaud URBINELLI
Contact
etudes@clin-experts.fr
+33756882093
José GARCIA-MACE
Contact
Nicolas ROCHE
principal investigator · HOPITAL COCHIN

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion